Risk factors for progression or death after first-line platinum-based chemotherapy in real-world patients in theUSA with ovarian cancer from 2011 to 2018.

Abstract

Aim: Patient chart data from theUSA during the period of January 2011 through October 2018 were used to assess risk factors for progression in advanced ovarian cancerafter response to first-line platinum-based chemotherapy. Patients & methods: Patients with stage III/IV ovarian cancer who completed first-line platinum-based chemotherapy after primary or interval debulking surgery were identified from the Flatiron Health database. Cox proportional hazards modeling was used to assess associations between baseline factors and time to next treatment (TTNT) or overall survival (OS). Results: Patients at stage IV or who received interval debulking surgery had shorter TTNT and OS than patients at stage III or who received primarydebulking surgery, respectively. OS was worse in patients with residual disease and in BRCA wild-type. Conclusion: Multiple factors were associated with shorter TTNT or OS in this retrospective real-world analysis.